Organised by the European Hematology Association and EBMT
Dates4–6 Feb 2027
VenueCentro de Congressos de Lisboa
CityLisbon, Portugal
A three-day in-person European CAR T-cell meeting in Lisbon from EHA and EBMT, covering clinical, translational and operational aspects of CAR T therapy.
Reviewed byDr Robert Baxter· Junior Clinical Fellow, Acute Medical Unit· Updated 16 Jul 2026
MedicMess Conference Intelligence
Networking
The in-person-only format includes coffee breaks, welcome reception, lunch and poster sessions.
Research Value
Regular and late-breaker abstract/clinical case routes are available, with oral sessions and poster sessions visible in the programme.
Trainee Relevance
EHA Junior member / EBMT Trainee member pricing is EUR 100 across early, regular and onsite windows.
Audience
Haematologists, oncologists, physicians, nurses, data managers, supply-chain managers and patient-organisation representatives working around CAR T-cell therapy.
Programme Highlights
Key Themes
Clinical CAR T-cell therapyToxicity managementTranslational CAR T scienceManufacturing and engineeringAccess and models of careReal-world nursing practice
One simple graph/image; JPEG, TIF or GIF; max 500 KB
Character Limit
3,500 characters including spaces, punctuation and template headers
Regular Deadline
14 November 2026, 23:59 CET
Late Breaking Deadline
8 January 2027, 23:59 CET
Categories & Recommended Topics
CAR-based Cellular Therapy - Clinical
Biomarkers for CAR T efficacy and prediction models
Challenges of CAR-based cellular therapy
Clinical applications in oncology and other fields
Management of toxicities
CAR-based Cellular Therapy - Preclinical
CAR T cell manufacturing methodologies
Innovative T cell engineering and CAR design
Mechanistic studies of efficacy, toxicities and tumour resistance
Clinical cases
Access to CAR T
Multidisciplinary CAR T models of care
Real-world nursing practice
MedicMess Tips
Early registration closes 9 December 2026 at 23:59 CET; regular registration closes 3 February 2027.
The meeting is fully in person with no livestream or virtual platform.
Late-breaker abstracts open 1 January 2027 and close 8 January 2027.
Cost & Registration
Category
Price
Early bird registration
€510
Standard registration
€675
Trainee / IMT
€100
Medical student
€305
Key Deadlines
14 Nov 2026 · 121 days
Abstract submission deadline
3 Feb 2027 · 202 days
Registration deadline
4 Feb 2027 · 203 days
Conference begins
Practical Information
Travel NoteParticipants are responsible for their own travel and accommodation; visa letters are available after completing registration.
AccommodationSelected hotel links are provided in registration confirmation emails.
Venue DetailsCentro de Congressos de Lisboa, Praça das Indústrias 1, 1300-307 Lisbon, Portugal
Conference Snapshot
Specialty
Haematology
Organising society
European Hematology Association and EBMT
Conference format
In-person only
Location
Centro de Congressos de Lisboa, Lisbon
The Complete Guide to the EHA-EBMT 9th European CAR T-cell Meeting
The ninth EHA-EBMT European CAR T-cell Meeting takes place in Lisbon from 4 to 6 February 2027. It is fully in person and targets haematologists, oncologists, physicians, nurses, data managers, supply chain managers and patient-organisation representatives. The programme covers clinical successes and remaining challenges, toxicity management, long-term safety and efficacy, scientific innovation, real-world application and emerging indications. The linked programme at a glance already shows keynote, scientific, oral, poster, translational and satellite sessions across the meeting. Abstract and clinical case submission is open from 1 July 2026 with a regular deadline of 14 November 2026, notification by 1 December and a withdrawal deadline of 15 December. A late-breaker route opens on 1 January 2027 and closes on 8 January. Registration tiers are published in euros for physicians, other professionals, nurses, junior/trainee members and industry representatives, with early, regular and onsite windows. The venue is Centro de Congressos de Lisboa; livestream access is explicitly not offered.
Dr Robert Baxter